Compare SDOT & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDOT | AZTR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.5M |
| IPO Year | 2019 | 2023 |
| Metric | SDOT | AZTR |
|---|---|---|
| Price | $0.28 | $0.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 14.5M | 465.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 490.91 | 5.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,929,137.00 | N/A |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 60.08 | N/A |
| 52 Week Low | $0.24 | $0.10 |
| 52 Week High | $13.02 | $1.40 |
| Indicator | SDOT | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 22.36 | 50.81 |
| Support Level | $0.24 | $0.21 |
| Resistance Level | $0.96 | $0.26 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 2.53 | 42.09 |
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.